ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1290

Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy

Iago Pinal-Fernandez1, Maria Casal-Dominguez 1, Assia Derfoul 1, Katherine Pak 1, Paul Plotz 1, Frederick W. Miller 2, Jose C Milisenda 3, Josep M Grau-Junyent 3, Albert Selva-O'Callaghan 4, Julie Paik 5, Jemima Albayda 6, Lisa Christopher-Stine 7, Thomas E Lloyd 5, Andrea M Corse 5 and Andrew L Mammen 1, 1National Institutes of Health, Bethesda, 2NIEHS, NIH, Bethesda, MD, 3Clinic Hospital, Barcelona, 4Department of Systemic Autoimmune Diseases, Hospital Universitario Valle de Hebron, Barcelona, Spain, Barcelona, 5Johns Hopkins, Baltimore, 6Johns Hopkins University, Baltimore, MD, 7Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: dermatomyositis, Gene Expression, interferons and ibm, polymyositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Muscle Biology, Myositis & Myopathies Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Activation of the type 1 interferon (IFN1) pathway is a prominent feature of dermatomyositis (DM) muscle and may play a role in the pathogenesis of this disease. However, the relevance of the IFN1 pathway in patients with other types of myositis, such as the antisynthetase syndrome (AS), immune-mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM), is largely unknown. Moreover, the activation of the type 2 interferon (IFN2) pathway has not been comprehensively explored in myositis. In this cross-sectional study, our objective was to analyze both IFN1 and IFN2 pathway activation in myositis by performing RNAseq on muscle biopsy samples from 119 patients with DM, IMNM, AS, or IBM as well as on 20 normal muscle biopsies.

Methods: The expression of IFN1- and IFN2-inducible genes was compared between the different groups.

Results: The expression of IFN1-inducible genes was high in DM, moderate in AS, and low in IMNM and IBM. In contrast, the expression of IFN2-inducible genes was high in DM, IBM, and AS but low in IMNM. The expression of IFN-inducible genes correlated with the expression of genes associated with inflammation and muscle regeneration. Of note, ISG15 expression levels alone performed as well as composite scores relying on multiple genes to monitor activation of the IFN1 pathway in myositis muscle biopsies.

Conclusion: IFN1 and IFN2 pathways are differentially activated in different forms of myositis. This observation may have therapeutic implications since immunosuppressive medications may preferentially target each of these pathways.


Disclosure: I. Pinal-Fernandez, None; M. Casal-Dominguez, None; A. Derfoul, None; K. Pak, None; P. Plotz, None; F. Miller, aTyr Pharma, 9, Biogen, 9, Hope Pharmaceuticals, 9, Idera Pharmaceuticals, 9, MedImmune, 9, Momenta Pharmaceuticals, 9; J. Milisenda, None; J. Grau-Junyent, None; A. Selva-O'Callaghan, None; J. Paik, None; J. Albayda, None; L. Christopher-Stine, AstraZeneca (Medimmune) Kezar, 5, Corbus Pharmaceuticals, 2, CSL Behring, 2, Inova Diagnostics, 7, Kezar, 2, Mallinckrodt Pharmaceuticals, 5, Novartis, 2, OptionCare, 5, Pfizer, 2; T. Lloyd, None; A. Corse, None; A. Mammen, None.

To cite this abstract in AMA style:

Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, Miller F, Milisenda J, Grau-Junyent J, Selva-O'Callaghan A, Paik J, Albayda J, Christopher-Stine L, Lloyd T, Corse A, Mammen A. Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/identification-of-distinctive-interferon-gene-signatures-in-different-types-of-inflammatory-myopathy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-distinctive-interferon-gene-signatures-in-different-types-of-inflammatory-myopathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology